Ember Therapeutics Inc
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport'… Read more
Ember Therapeutics Inc (EMBT) - Total Assets
Latest total assets as of September 2015: $2.30K USD
Based on the latest financial reports, Ember Therapeutics Inc (EMBT) holds total assets worth $2.30K USD as of September 2015.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ember Therapeutics Inc - Total Assets Trend (2012–2014)
This chart illustrates how Ember Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ember Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2014)
Ember Therapeutics Inc's total assets of $2.30K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 100.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2014)
This chart illustrates how Ember Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ember Therapeutics Inc's current assets represent 100.0% of total assets in 2014, unchanged from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 100.0% of total assets in 2014, the same as 100.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Ember Therapeutics Inc Competitors by Total Assets
Key competitors of Ember Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Ember Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ember Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ember Therapeutics Inc is currently not profitable relative to its asset base.
Ember Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.01 | 0.01 |
| Quick Ratio | 0.01 | 0.01 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-252.50K | $ -232.41K | $ -215.23K |
Ember Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Ember Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -85.3% |
| Total Assets | $184.00 |
| Market Capitalization | $0.94 USD |
Valuation Analysis
Below Book Valuation: The market values Ember Therapeutics Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ember Therapeutics Inc's assets decreased by 85.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ember Therapeutics Inc (2012–2014)
The table below shows the annual total assets of Ember Therapeutics Inc from 2012 to 2014.
| Year | Total Assets | Change |
|---|---|---|
| 2014-12-31 | $184.00 | -85.34% |
| 2013-12-31 | $1.25K | -46.46% |
| 2012-12-31 | $2.34K | -- |